GLOW: Side Effects & Safety

Cosmetic peptides as a class have demonstrated a favorable safety profile in published research. GLOW contains bioactive peptide sequences with established safety records from individual component studies. As with all injectable peptide formulations, the primary risks are related to the injection process and individual sensitivity rather than systemic toxicity.

• Injection site reactions: Mild redness, swelling, or bruising at the injection site — the most commonly reported effect, typically resolving within 24–48 hours
• Skin sensitivity: Temporary increased skin sensitivity or mild tingling in some individuals, particularly during the first 1–2 weeks
• Flushing: Transient facial or body flushing, typically lasting minutes
• Headache: Occasional mild headache, more common in the first few doses

Key considerations for GLOW peptide research:

• Long-term safety data for injectable peptide blends remains limited compared to individual peptide components
• Peptide blends may have interactions not observed with individual components alone
• Quality and purity of the formulation are critical — source from reputable suppliers with third-party testing
• Not studied in pregnant or breastfeeding individuals

• Known hypersensitivity to any peptide component
• Active skin infections at intended injection sites
• History of keloid scarring (injection sites may be affected)
• Autoimmune skin conditions — peptides that modulate immune signaling may theoretically influence autoimmune processes
• Active cancer — growth factor-mimicking peptides require caution in individuals with active malignancies

Return to the GLOW peptide overview for general information.